CA2540586A1 - Traitement d'un trouble chez un mammifere par administration d'une sucre amine et utilisations associees - Google Patents

Traitement d'un trouble chez un mammifere par administration d'une sucre amine et utilisations associees Download PDF

Info

Publication number: CA2540586A1
Authority: CA; Canada
Prior art keywords: aminosugar; group; infra; cartilage; joint
Prior art date: 2003-10-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002540586A

Other languages

English (en)

Inventor

Youe-Kong Shue

Franklin W. Okumu

Alexander R. Shikhman

Martin Lotz

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Scripps Research Institute

Optimer Pharmaceuticals LLC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-01

Filing date

2004-09-30

Publication date

2005-04-21

2004-09-30 Application filed by Individual filed Critical Individual

2005-04-21 Publication of CA2540586A1 publication Critical patent/CA2540586A1/fr

Status Abandoned legal-status Critical Current

Links

150000002337 glycosamines Chemical class 0.000 title claims abstract description 55
241000124008 Mammalia Species 0.000 title claims abstract description 26
201000004595 synovitis Diseases 0.000 claims abstract description 26
230000007170 pathology Effects 0.000 claims abstract description 25
206010051763 Bone marrow oedema Diseases 0.000 claims abstract description 20
230000008355 cartilage degradation Effects 0.000 claims abstract description 15
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 93
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 92
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 90
229950006780 n-acetylglucosamine Drugs 0.000 claims description 81
238000000034 method Methods 0.000 claims description 61
239000000203 mixture Substances 0.000 claims description 46
210000000845 cartilage Anatomy 0.000 claims description 32
238000009472 formulation Methods 0.000 claims description 31
201000008482 osteoarthritis Diseases 0.000 claims description 26
230000001575 pathological effect Effects 0.000 claims description 25
239000000499 gel Substances 0.000 claims description 19
150000001875 compounds Chemical class 0.000 claims description 18
239000011159 matrix material Substances 0.000 claims description 18
238000002347 injection Methods 0.000 claims description 17
239000007924 injection Substances 0.000 claims description 17
229920000642 polymer Polymers 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 13
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 12
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 8
229960002442 glucosamine Drugs 0.000 claims description 8
238000013270 controlled release Methods 0.000 claims description 7
239000007972 injectable composition Substances 0.000 claims description 7
239000004005 microsphere Substances 0.000 claims description 7
206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
239000000725 suspension Substances 0.000 claims description 7
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 6
239000007943 implant Substances 0.000 claims description 6
239000002245 particle Substances 0.000 claims description 6
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 5
238000007918 intramuscular administration Methods 0.000 claims description 5
NJOZFAFEQVQFJI-KVTDHHQDSA-N (2r,3r,4r,5r)-2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound NC[C@H]1N[C@H](CO)[C@@H](O)[C@@H]1O NJOZFAFEQVQFJI-KVTDHHQDSA-N 0.000 claims description 4
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims description 4
229940124599 anti-inflammatory drug Drugs 0.000 claims description 4
239000002502 liposome Substances 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
239000003112 inhibitor Substances 0.000 claims description 3
239000003550 marker Substances 0.000 claims 5
238000001802 infusion Methods 0.000 claims 3
238000002648 combination therapy Methods 0.000 claims 2
238000010254 subcutaneous injection Methods 0.000 claims 2
239000007929 subcutaneous injection Substances 0.000 claims 2
239000000017 hydrogel Substances 0.000 claims 1
238000011065 in-situ storage Methods 0.000 claims 1
239000002077 nanosphere Substances 0.000 claims 1
238000007920 subcutaneous administration Methods 0.000 claims 1
241000283973 Oryctolagus cuniculus Species 0.000 description 24
239000004480 active ingredient Substances 0.000 description 22
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
239000000243 solution Substances 0.000 description 17
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 15
210000001264 anterior cruciate ligament Anatomy 0.000 description 15
239000003814 drug Substances 0.000 description 15
229920002674 hyaluronan Polymers 0.000 description 15
OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 14
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 14
229940079593 drug Drugs 0.000 description 13
230000000877 morphologic effect Effects 0.000 description 13
239000011780 sodium chloride Substances 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 11
230000003902 lesion Effects 0.000 description 11
206010063045 Effusion Diseases 0.000 description 10
241001465754 Metazoa Species 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
230000007850 degeneration Effects 0.000 description 10
229920002683 Glycosaminoglycan Polymers 0.000 description 9
210000001188 articular cartilage Anatomy 0.000 description 9
230000003011 chondroprotective effect Effects 0.000 description 9
230000000694 effects Effects 0.000 description 9
210000003127 knee Anatomy 0.000 description 9
210000000629 knee joint Anatomy 0.000 description 9
229920000747 poly(lactic acid) Polymers 0.000 description 9
230000009467 reduction Effects 0.000 description 9
239000002904 solvent Substances 0.000 description 9
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
229960003160 hyaluronic acid Drugs 0.000 description 8
230000004054 inflammatory process Effects 0.000 description 8
239000004626 polylactic acid Substances 0.000 description 8
210000001258 synovial membrane Anatomy 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
229920002385 Sodium hyaluronate Polymers 0.000 description 7
229960002903 benzyl benzoate Drugs 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
210000001612 chondrocyte Anatomy 0.000 description 7
229920001577 copolymer Polymers 0.000 description 7
201000010099 disease Diseases 0.000 description 7
229940099552 hyaluronan Drugs 0.000 description 7
239000008194 pharmaceutical composition Substances 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
229940010747 sodium hyaluronate Drugs 0.000 description 7
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
230000002146 bilateral effect Effects 0.000 description 6
-1 cyclic aminosugar Chemical class 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
206010023232 Joint swelling Diseases 0.000 description 5
239000000463 material Substances 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
210000005065 subchondral bone plate Anatomy 0.000 description 5
235000000346 sugar Nutrition 0.000 description 5
238000013268 sustained release Methods 0.000 description 5
239000012730 sustained-release form Substances 0.000 description 5
210000005222 synovial tissue Anatomy 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000036512 infertility Effects 0.000 description 4
208000014674 injury Diseases 0.000 description 4
210000001503 joint Anatomy 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 4
238000010186 staining Methods 0.000 description 4
230000008961 swelling Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
210000002303 tibia Anatomy 0.000 description 4
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
229920002101 Chitin Polymers 0.000 description 3
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000000589 Interleukin-1 Human genes 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229940072056 alginate Drugs 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
239000002260 anti-inflammatory agent Substances 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
206010061592 cardiac fibrillation Diseases 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
150000002016 disaccharides Chemical group 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
238000005538 encapsulation Methods 0.000 description 3
230000002600 fibrillogenic effect Effects 0.000 description 3
150000004676 glycans Chemical class 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000008736 traumatic injury Effects 0.000 description 3
210000000689 upper leg Anatomy 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
206010007710 Cartilage injury Diseases 0.000 description 2
229920001661 Chitosan Polymers 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
208000003456 Juvenile Arthritis Diseases 0.000 description 2
206010029113 Neovascularisation Diseases 0.000 description 2
241000906034 Orthops Species 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
150000001558 benzoic acid derivatives Chemical class 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000000562 conjugate Chemical class 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000008298 dragée Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
210000000281 joint capsule Anatomy 0.000 description 2
239000006193 liquid solution Substances 0.000 description 2
239000006194 liquid suspension Substances 0.000 description 2
238000011068 loading method Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000011587 new zealand white rabbit Methods 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
210000001179 synovial fluid Anatomy 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
238000013257 ACL transection animal model Methods 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
241000238424 Crustacea Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
229920000288 Keratan sulfate Polymers 0.000 description 1
208000003947 Knee Osteoarthritis Diseases 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
101100074988 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nmp-1 gene Proteins 0.000 description 1
101100074998 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nmp-2 gene Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
206010048873 Traumatic arthritis Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
238000003287 bathing Methods 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
238000010367 cloning Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000005786 degenerative changes Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000021004 dietary regimen Nutrition 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000011496 digital image analysis Methods 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
210000002745 epiphysis Anatomy 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
239000013022 formulation composition Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
RJTZUHVCZIGJMB-UHFFFAOYSA-N hydron;1h-indole;chloride Chemical compound Cl.C1=CC=C2NC=CC2=C1 RJTZUHVCZIGJMB-UHFFFAOYSA-N 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
208000018937 joint inflammation Diseases 0.000 description 1
201000004990 juvenile ankylosing spondylitis Diseases 0.000 description 1
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
NZEVKZAEMSMLMC-UHFFFAOYSA-N nmp-7 Chemical compound C=1C=C2N(CCCCC)C3=CC=CC=C3C2=CC=1C(=O)N1CCCCC1 NZEVKZAEMSMLMC-UHFFFAOYSA-N 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000004768 organ dysfunction Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
230000003349 osteoarthritic effect Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
210000004417 patella Anatomy 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
210000002967 posterior cruciate ligament Anatomy 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
239000004332 silver Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
230000008719 thickening Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

CA002540586A 2003-10-01 2004-09-30 Traitement d'un trouble chez un mammifere par administration d'une sucre amine et utilisations associees Abandoned CA2540586A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US50771603P	2003-10-01	2003-10-01
US60/507,716		2003-10-01
PCT/US2004/032048 WO2005034961A1 (fr)	2003-10-01	2004-09-30	Traitement d'un trouble chez un mammifere par administration d'une sucre amine et utilisations associees

Publications (1)

Publication Number	Publication Date
CA2540586A1 true CA2540586A1 (fr)	2005-04-21

Family

ID=34434891

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002540586A Abandoned CA2540586A1 (fr)	2003-10-01	2004-09-30	Traitement d'un trouble chez un mammifere par administration d'une sucre amine et utilisations associees

Country Status (5)

Country	Link
EP (1)	EP1670486A4 (fr)
JP (1)	JP2007507516A (fr)
CN (1)	CN1909911A (fr)
CA (1)	CA2540586A1 (fr)
WO (1)	WO2005034961A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005072268A2 (fr) *	2004-01-20	2005-08-11	Optimer Pharmaceuticals, Inc.	Traitement des pathologies cartilagineuses degeneratives chez les mammiferes au moyen d'inhibiteurs de la glycosidase
EP2318014B1 (fr) *	2008-07-18	2016-09-14	Genís hf.	Nouvelle composition pour le traitement de troubles auto-immuns
KR101098581B1 (ko) *	2009-01-09	2011-12-26	서울대학교산학협력단	Ａｂｈ 항원을 이용한 염증질환 개선용 조성물
JP2013543898A (ja) *	2010-11-24	2013-12-09	デュレクトコーポレイション	生体分解性薬物送達組成物
CN102614111B (zh) *	2012-04-05	2013-11-06	苏州豫源生物医药有限公司	氨基葡萄糖的凝胶剂及其制备方法
CN105884720A (zh) *	2016-04-23	2016-08-24	陈斌	一种盐酸丁螺环酮的药物组合物及其医药用途
WO2020104833A1 (fr) *	2018-11-19	2020-05-28	4P-Pharma	Composition et procédés pour réguler la prolifération de chondrocytes et augmenter la production de matrice cartilagineuse
CN112169713A (zh) *	2020-09-09	2021-01-05	江南大学	一种n-烷基乳糖胺表面活性剂小分子醇凝胶及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3927723A1 (de) *	1989-01-26	1990-08-02	Ulrich Prof Dr Speck	N - acetylglucosamin zur buccalen anwendung
AUPM666894A0 (en) *	1994-07-07	1994-07-28	University Of Melbourne, The	Diagnostic methods and compositions
WO1997021434A1 (fr) *	1995-12-11	1997-06-19	Inholtra, Inc.	Regime alimentaire a base de complements nutritionnels permettant de soulager les symptomes de l'arthrite
US5840715A (en) *	1995-12-11	1998-11-24	Inholtra Investment Holdings & Trading, N.V.	Dietary regimen of nutritional supplements for relief of symptoms of arthritis
CA2274510C (fr) *	1996-12-13	2010-02-16	Lescarden, Inc.	Traitement de l'arthrose par administration de poly-n-acetyl-d-glucosamine
US6514983B1 (en) *	1997-09-03	2003-02-04	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6514522B2 (en) *	1998-04-08	2003-02-04	Chondros, Inc.	Polymer constructs
US6378527B1 (en) *	1998-04-08	2002-04-30	Chondros, Inc.	Cell-culture and polymer constructs
JP2002515488A (ja) *	1998-05-15	2002-05-28	ギルフォードファーマシューティカルズインコーポレイテッド	カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
US6506785B2 (en) *	1998-05-22	2003-01-14	Pfizer, Inc.	Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
US6346519B1 (en) *	1998-09-09	2002-02-12	Advanced Medical Instruments	Method and composition for treating arthritis
US6656925B2 (en) *	1998-09-09	2003-12-02	Advanced Medical Instruments	Composition and method of treating arthritis
US6662805B2 (en) *	1999-03-24	2003-12-16	The Johns Hopkins University	Method for composite cell-based implants
ATE424111T1 (de) *	2001-03-29	2009-03-15	Scripps Research Inst	Formulierungen, die eingeschlossene wirkstoffe enthalten, und ihre verwendung
IS6085A (is) *	2001-09-26	2003-03-27	Genis Ehf.	Lyfjablanda með kítósan óligómerum
MXPA01011542A (es) *	2001-11-13	2003-05-22	Alcon Inc	Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
JP2003225093A (ja) *	2001-11-30	2003-08-12	Sumitomo Pharmaceut Co Ltd	軟骨障害マーカー及びその利用
GEP20063951B (en) *	2001-11-30	2006-10-25	Pfizer	Controlled release polymeric compositions of bone growth promoting compounds

2004
- 2004-09-30 EP EP04789289A patent/EP1670486A4/fr not_active Withdrawn
- 2004-09-30 JP JP2006534068A patent/JP2007507516A/ja active Pending
- 2004-09-30 WO PCT/US2004/032048 patent/WO2005034961A1/fr not_active Ceased
- 2004-09-30 CA CA002540586A patent/CA2540586A1/fr not_active Abandoned
- 2004-09-30 CN CNA2004800323746A patent/CN1909911A/zh active Pending

Also Published As

Publication number	Publication date
WO2005034961A1 (fr)	2005-04-21
EP1670486A4 (fr)	2009-04-01
JP2007507516A (ja)	2007-03-29
CN1909911A (zh)	2007-02-07
EP1670486A1 (fr)	2006-06-21

Legal Events

Date	Code	Title	Description
2009-09-24	EEER	Examination request
2011-09-30	FZDE	Dead

Publication	Publication Date	Title
JP6113424B2 (ja)	2017-04-12	安定化された多糖の処方のための組成物及び方法
Brandt	1987	Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo
Shikhman et al.	2005	Chondroprotective activity of N-acetylglucosamine in rabbits with experimental osteoarthritis
CA2653660C (fr)	2014-07-29	Acide hyaluronique sulfate destine au traitement de l'arthrose degenerative
US9216193B2 (en)	2015-12-22	Crosslinked hyaluronic acid composition and self-crosslinking hyaluronic acid particles
JP5291621B2 (ja)	2013-09-18	関節疾患に対する持続的治療効果を有する薬剤
US20230190786A1 (en)	2023-06-22	Continuous release compositions made from hyaluronic acid, and therapeutic applications of same
CN114010640A (zh)	2022-02-08	创伤后骨关节炎的预防性治疗
EP3463304A1 (fr)	2019-04-10	Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations
JP2016132669A (ja)	2016-07-25	関節を治療するための組成物及び方法
JP5047814B2 (ja)	2012-10-10	骨関節症におけるヒアルロン酸のアミド誘導体
US20070142326A1 (en)	2007-06-21	Treatment of a condition in a mammal with administration of aminosugar and uses thereof
CA2540586A1 (fr)	2005-04-21	Traitement d'un trouble chez un mammifere par administration d'une sucre amine et utilisations associees
KR20250134143A (ko)	2025-09-09	골관절염과 같은 관절 질환의 치료에서 사용하기 위한 콜키신을 포함하는 관절내 주사용 제형
US20070197471A1 (en)	2007-08-23	Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors
WO2010017265A2 (fr)	2010-02-11	Compositions injectables à libération prolongée et méthodes de traitement de l’arthrite avec celles-ci
CN101141968A (zh)	2008-03-12	给予化合物治疗哺乳动物的病况及其应用方法
WO2025085109A2 (fr)	2025-04-24	Procédés de prévention d'arthrose post-traumatique à l'aide de metformine
KR20190140190A (ko)	2019-12-19	디아세린 나노입자를 포함하는 관절강 주사용 조성물 및 이의 용도
HK1197040B (en)	2018-01-12	Sulphated hyaluronic acid for treating degenerative osteoarthritis